Lonza Netherlands, former PharmaCell Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Lonza Netherlands, former PharmaCell's estimated annual revenue is currently $47M per year.
- Lonza Netherlands, former PharmaCell's estimated revenue per employee is $201,000
- Lonza Netherlands, former PharmaCell has 234 Employees.
- Lonza Netherlands, former PharmaCell grew their employee count by 35% last year.
- Lonza Netherlands, former PharmaCell currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
What Is Lonza Netherlands, former PharmaCell?
Lonza Netherlands is a Contract Manufacturing Organization (CMO) in the area of cell therapy and regenerative medicine (tissue culturing). The company works with European and US-based biotechnology companies on pre-clinical, clinical to commercial development projects and offers GMP and regulatory consultancy, cell culturing process development, fill and finish, Quality Control (QC)-testing and Good Manufacturing Practices (GMP) production services, as well as storage and distribution of clinical trial materials. PharmaCell is located in the center of Europe and operates two state-of-the-art cGMP-licensed facilities for human cell & tissue culturing in Maastricht and Geleen (Netherlands), conveniently located at approximately one hour driving distance from Brussels, Antwerp, Cologne and Dusseldorf.keywords:N/A
Number of Employees
Employee Growth %
Lonza Netherlands, former PharmaCell News
Lonza will construct suites at its site in The Netherlands dedicated to producing ... did not divulge financial terms of the deal but old Bioprocess Insider his ... gene therapy network through the acquisition of PharmaCell in 2017.
The acquisition of Dutch commercial cell and gene therapy maker PharmaCell places Lonza as the leading CDMO in the space, the firm says.
Visp, Switzerland-based Lonza has acquired Dutch gene and cell contract therapy manufacturer PharmaCell because of its expertise with ...